MYL Related Upgrades
-
Leerink Swann Upgrades Mylan (MYL) to Outperform
-
Canaccord Genuity Upgrades Mylan (MYL) to Buy; Set to Break-Out
-
Goldman Sachs Adds Watson Pharmaceuticals (WPI) to Conviction Buy List, Cheap Vs. Peers
-
Goldman Sachs Upgrades Mylan (MYL) to Buy, Sees Earnings Revised Higher
-
Morgan Stanley Upgrades Mylan (MYL) to Overweight, Downgrades Watson (WPI) to Equalweight
-
Argus Upgrades Mylan (MYL) to Buy
-
Goldman Sachs Added Mylan (MYL) to Conviction Buy List
-
Bernstein Upgrades Mylan (MYL) to Outperform
-
Goldman Sachs Raises Price Targets for Healthcare Services; Upgrades ABC, Downgrades PSSI
-
Standard & Poor's Upgrades Mylan (MYL) Credit Rating to 'BB'
-
Barclays Upgrades Mylan (MYL) to Overweight
-
Wachovia Upgraded the Generic Drug Sector to Overweight; Ups TEVA and WPI to Overweight
-
Buckingham Research Upgrades Mylan (MYL) to Strong Buy
-
Citi Upgrades Mylan (MYL) to Buy
-
Morgan Stanley Upgrades Mylan (MYL) to Overweight
-
Goldman Sachs upgrades Mylan (MYL) to Buy
-
Merrill Lynch upgrades Mylan (MYL) to Buy
-
Bernstein upgrades Mylan (MYL) to Outperform
-
Credit Suisse upgrades Mylan Labs (MYL) to Outperform
-
UBS upgrades Mylan Labs (MYL) to Buy
-
Merrill Lynch upgrades Mylan Labs (MYL) to Neutral
-
Wachovia upgrades MYL to Outperform
-
Buckingham upgrades FRX to Accumulate
-
Lehman Brothers upgrades MYL to Overweight
Back to MYL Stock Lookup
